Date:- 8 January, 2019
Tag:- IMMUNOSCORE® in Colon Cancer
HalioDx, an immuno-oncology company pioneering the immunological diagnosis of cancers, today announced that the company is expanding its North American operations with the inception of HalioDx Inc., located in Richmond, Virginia. The facility holds a CLIA certificate of registration for its flagship Immunoscore® assay and is now ready to receive and run samples. In parallel HalioDx has recruited a seasoned sales force and started the implementation of its reimbursement roadmap. Immmunoscore® is a breakthrough immunohistochemistry assay powered by image analysis enabling to improve the management of localized colon cancer.
“After developing our international commercial network via distributors covering year-to-date 19 countries, we have now, with the opening of our Richmond lab, the capacity to offer directly Immunoscore® to US and Latin America patients” said Stephane Debono, EVP of the Diagnostics Business Unit at HalioDx and CEO of HalioDx Inc.
“The North America market is critical for any innovative diagnostic company that has global ambition and opening our CLIA laboratory in Virginia plus building our own sales organization to serve directly US oncologists is a landmark for HalioDx. We expect also additional interest from Pharma as we are now able to run Immunoscore® closer to US clinical trials sites.” added Vincent Fert President and CEO of HalioDx.
HalioDx team is taking part in JP Morgan Healthcare conference January 7-10, in San Francisco, California. To schedule an appointment at the conference, please contact infos(at)haliodx(dot)com.